SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home order

Dietrich, M; Norton, Elizabeth B.; Elliott, Debra; Smira, Ashley; Raviv, Ofek; Sasson, Daniel J.; Monk, Chandler H.; Michael, Madalyn L.; Rogers, Nathaniel; Rouelle, Julie A.; Bond, Nell G.; Aime-Marcelin, Kéren; Prystowsky, Alisha; Kemnitz, Rebecca; Sarma, Arunava; Himmelfarb, Sarah Talia; Sharma, Neha; Stone, Addison E.; Craver, Randall; Lindrose, Alyssa R; Smitley, Leslie A.; Uddo, Robert B.; Myers, Leann; Drury, Stacy S.; Schieffelin, John S.; Robinson, James E.; Zwezdaryk, Kevin J.

doi:10.1016/j.jcvp.2021.100047

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the seroprevalence study, we tested residual blood samples that were collected between 18 March and 15 May 2020, from children ≤ 18 years of age from Children’s Hospital in New Orleans, Louisiana. Collection and processing have previously been described [ 12 ]. All serum samples were SARS-CoV-2 -negative and HIV-negative [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Novel Pneumocystis Antigens for Seroprevalence Studies

Pungan

Fan

Dai

et al. 2023

JoF

Self Cite

View full text Add to dashboard Cite

Pneumocystis jirovecii is the most common cause of fungal pneumonia in children under the age of 2 years. However, the inability to culture and propagate this organism has hampered the acquisition of a fungal genome as well as the development of recombinant antigens to conduct seroprevalence studies. In this study, we performed proteomics on Pneumocystis-infected mice and used the recent P. murina and P. jirovecii genomes to prioritize antigens for recombinant protein expression. We focused on a fungal glucanase due to its conservation among fungal species. We found evidence of maternal IgG to this antigen, followed by a nadir in pediatric samples between 1 and 3 months of age, followed by an increase in prevalence over time consistent with the known epidemiology of Pneumocystis exposure. Moreover, there was a strong concordance of anti-glucanase responses and IgG against another Pneumocystis antigen, PNEG_01454. Taken together, these antigens may be useful tools for Pneumocystis seroprevalence and seroconversion studies.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Collection and processing have previously been described [ 12 ]. All serum samples were SARS-CoV-2 -negative and HIV-negative [ 12 ]. For the ELISA assays, Maxisorp plates (ThermoFisher cat.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Novel Pneumocystis Antigens for Seroprevalence Studies

Pungan

Fan

Dai

et al. 2023

JoF

Self Cite

View full text Add to dashboard Cite

show abstract

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

Figueiredo

Hirsch

Kushi

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Global efforts are needed to elucidate the epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the underlying cause of coronavirus disease 2019 (COVID-19) including seroprevalence, risk factors and long-term sequelae, as well as immune responses following vaccination across populations and the social dimensions of prevention and treatment strategies. In the U.S., the National Cancer Institute in partnership with the National Institute of Allergy and Infectious Diseases, established the SARS-CoV-2 Serological Sciences Network (SeroNet) as the nation’s largest coordinated effort to study COVID-19. The network is comprised of multidisciplinary researchers bridging gaps and fostering collaborations between immunologists, epidemiologists, virologists, clinicians and clinical laboratories, social and behavioral scientists, policy makers, data scientists, and community members. In total, 49 institutions form the SeroNet consortium to study individuals with cancer, autoimmune disease, inflammatory bowel diseases, cardiovascular diseases, HIV, transplant recipients, as well as otherwise healthy pregnant women, children, college students, and high-risk occupational workers (including health care workers and first responders). Several studies focus on underrepresented populations, including ethnic minorities and rural communities. To support integrative data analyses across SeroNet studies, efforts are underway to define common data elements for standardized serology measurements, cellular and molecular assays, self-reported data, treatment, and clinical outcomes. In this paper, we discuss the overarching framework for SeroNet epidemiology studies, critical research questions under investigation, and data accessibility for the worldwide scientific community. Lessons learned will help inform preparedness and responsiveness to future emerging diseases.

show abstract

SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background Covid-19 has been one of the major concerns around the world in the last 2 years. One of the challenges of this disease has been to determine its prevalence. Conflicting results of the serology test in Covid explored the need for an updated meta-analysis on this issue. Thus, this systematic review aimed to estimate the prevalence of global SARS-CoV-2 serology in different populations and geographical areas. Methods To identify studies evaluating the seroprevalence of SARS-CoV-2, a comprehensive literature search was performed from international databases, including Medline (PubMed), Web of Sciences, Scopus, EMBASE, and CINHAL. Results In this meta-analysis, the results showed that SARS-CoV-2 seroprevalence is between 3 and 15% worldwide. In Eastern Mediterranean, the pooled estimate of seroprevalence SARS-CoV-2 was 15% (CI 95% 5–29%), and in Africa, the pooled estimate was 6% (CI 95% 1–13%). In America, the pooled estimate was 8% (CI 95% 6–11%), and in Europe, the pooled estimate was 5% (CI 95% 4–6%). Also the last region, Western Pacific, the pooled estimate was 3% (CI 95% 2–4%). Besides, we analyzed three of these areas separately. This analysis estimated the prevalence in subgroups such as study population, diagnostic methods, sampling methods, time, perspective, and type of the study. Conclusion The present meta-analysis showed that the seroprevalence of SARS-CoV-2 has been between 3 and 15% worldwide. Even considering the low estimate of this rate and the increasing vaccination in the world, many people are still susceptible to SARS-CoV-2.

show abstract

SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home order

Cited by 3 publications

References 9 publications

Novel Pneumocystis Antigens for Seroprevalence Studies

Novel Pneumocystis Antigens for Seroprevalence Studies

Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies

SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis

Contact Info

Product

Resources

About